Oligonucleotide Synthesis Market Regional Insights

The global oligonucleotide synthesis market is demonstrating strong momentum, rising from US$8.9 billion in 2024 to US$10.5 billion in 2025. It is projected to grow at a robust CAGR of 18.6% during 2025–2030, ultimately reaching US$24.7 billion by 2030. The market’s rapid expansion reflects the accelerating role of oligonucleotides in therapeutics, diagnostics, and research applications—especially in gene therapy, molecular diagnostics, and synthetic biology.

Market Momentum & Strategic Outlook

The oligonucleotide synthesis market has transitioned from a niche scientific process to a critical enabler of next-generation biotechnologies. Rising investments in genomic research, the growing pipeline of oligonucleotide-based drugs, and the demand for custom DNA and RNA sequences are propelling market growth.

• Biopharmaceutical expansion: Pharmaceutical companies are increasingly adopting synthetic oligonucleotides for developing targeted therapies for rare diseases, cancer, and infectious disorders.
• Technological advancement: Innovations in solid-phase synthesis, automated DNA synthesizers, and high-throughput platforms have significantly reduced costs and turnaround times.
• Strategic consolidation: Major industry players are focusing on mergers and acquisitions to expand production capacity and strengthen integrated service offerings. For example, companies are integrating oligonucleotide synthesis with bioinformatics and CRISPR-based design capabilities to streamline R&D workflows.

The outlook remains positive as governments and research institutes continue investing in genomic sequencing and personalized medicine programs, creating sustained demand for high-quality oligonucleotides.

Regional Analysis

North America remains the largest market, driven by a strong biotechnology ecosystem, advanced healthcare infrastructure, and substantial government funding for genomics research. The U.S. leads in oligonucleotide therapeutics development and commercialization, supported by FDA-approved drugs and an expanding network of contract manufacturing organizations (CMOs).

Europe follows closely, with key contributions from Germany, the UK, and France. The region benefits from collaborative R&D programs and increasing focus on RNA-based therapies and molecular diagnostics. The European Medicines Agency (EMA) continues to streamline approval pathways for oligonucleotide-based therapeutics, fostering market confidence.

Asia-Pacific (APAC) is the fastest-growing regional market, showing tremendous potential due to expanding biotech hubs in China, Japan, South Korea, and India. The region’s growth is supported by the proliferation of genomic startups, favorable government policies, and rising investments in synthetic biology and pharmaceutical research.

Other regions, including Latin America and the Middle East, are emerging markets with growing adoption of genetic testing, indicating untapped future opportunities for oligonucleotide suppliers and service providers.

Country Coverage

• United States: The U.S. dominates global revenue share owing to extensive oligonucleotide drug development pipelines, strong biotech funding, and the presence of major players like Thermo Fisher Scientific and Agilent Technologies.
• China: Fastest-growing market globally, fueled by national genomics initiatives, expansion of local CDMOs, and the rapid development of nucleic acid therapeutics manufacturing capacity.
• Germany and the UK: Strong research collaborations between universities and biotech firms support innovation in antisense and siRNA technologies.
• Japan: Known for technological precision and advanced automation in oligo synthesis equipment manufacturing.
• India: Emerging as a cost-effective outsourcing hub for oligonucleotide manufacturing and preclinical R&D services.

Key Highlights by Stakeholders

• Manufacturers: Leading companies such as Thermo Fisher Scientific, Merck KGaA, and Integrated DNA Technologies (IDT) are expanding their oligonucleotide synthesis portfolios to include long and modified oligos for therapeutic applications.
• Suppliers: Chemical and reagent suppliers are investing in improved raw material quality and supply chain stability to meet the growing demand for GMP-grade oligonucleotides.
• Investments & Announcements:
  • Multiple biotech firms have announced new synthesis facilities in the U.S. and APAC to reduce lead times and meet rising therapeutic production needs.
  • Government-backed genomic programs in China and Europe are boosting demand for custom oligos for research and diagnostic use.
  • Regulatory agencies are working to standardize quality and purity criteria for therapeutic oligonucleotides, further formalizing the industry landscape.

Key Strategies of Leading Companies

Top market participants are adopting multifaceted strategies to strengthen their market presence and ensure long-term growth:

• Partnerships & Collaborations: Strategic alliances between biotech companies, CMOs, and technology firms enable faster innovation cycles and capacity scalability.
• Product Innovation: Development of high-fidelity synthesis technologies and bioinformatics-driven design platforms enhance accuracy and customization.
• Capacity Expansion: Large-scale manufacturing facilities are being commissioned to support clinical and commercial-scale oligonucleotide production.
• Sustainability Initiatives: Companies are investing in green chemistry approaches to minimize solvent use and reduce environmental footprint.
• Digital Integration: AI-based synthesis planning tools and cloud-connected platforms are improving operational efficiency and product quality assurance.

Key Questions Answered by the Oligonucleotide Synthesis Market

Q1. What drives demand for oligonucleotide synthesis?
The rising use of oligonucleotides in gene editing, molecular diagnostics, and RNA-based therapeutics, coupled with advancements in automation and bioinformatics, is driving market demand.

Q2. Which region leads in adoption?
North America holds the largest market share, but Asia-Pacific is the fastest-growing due to expanding biotech investments and favorable government policies.

Q3. What are the main applications?
Applications span therapeutics (antisense, siRNA, mRNA), diagnostics (PCR, sequencing), and research (gene synthesis and cloning).

Q4. What challenges exist in the market?
High manufacturing costs, stringent regulatory requirements, and scalability issues for large-scale therapeutic production remain key challenges.

Q5. How are companies addressing future growth?
By investing in advanced synthesis platforms, sustainable manufacturing, and strategic collaborations with academic and clinical research centers to accelerate product development.

Conclusion
The oligonucleotide synthesis market stands at the forefront of modern biotechnology, poised for transformative growth. As demand for precision medicine, genetic therapies, and molecular diagnostics intensifies, industry stakeholders are rapidly advancing technologies, capacity, and global collaborations—ensuring the market’s sustained expansion well into the next decade.

Check out Related Reports to Oligonucleotide Synthesis Industry

Biomarkers Market

Synthetic Biology Market